Gao, J. et al. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat. Rev. Neurosci. 25, 553–572 (2024).
Winston, G., Kharas, N., Svenningsson, P., Jha, A. & Kaplitt, M. G. Gene therapy for Parkinson’s disease: trials and technical advances. Lancet Neurol. 24, 548–556 (2025).
Marks, W. J. Jr et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 7, 400–408 (2008).
Marks, W. J. Jr et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9, 1164–1172 (2010).
Warren Olanow, C. et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78, 248–257 (2015).
Heiss, J. D. et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson’s disease. Mov. Disord. 34, 1073–1078 (2019).
Bartus, R. T. et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80, 1698–1701 (2013).
Marks, W. J. Jr, Baumann, T. L. & Bartus, R. T. Long-term safety of patients with Parkinson’s disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum. Gene Ther. 27, 522–527 (2016).
Huttunen, H. J. et al. Intraputamenal cerebral dopamine neurotrophic factor in Parkinson’s disease: a randomized, double-blind, multicenter phase 1 trial. Mov. Disord. 38, 1209–1222 (2023).
Van Laar, A. D. et al. Intraputaminal delivery of adeno-associated virus serotype 2-glial cell line-derived neurotrophic factor in mild or moderate Parkinson’s disease. Mov. Disord. 40, 1297–1306 (2025).
Kaplitt, M. G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369, 2097–2105 (2007).
LeWitt, P. A. et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309–319 (2011).
Niethammer, M. et al. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease. JCI Insight 2, e90133 (2017).
Niethammer, M. et al. Gene therapy reduces Parkinson’s disease symptoms by reorganizing functional brain connectivity. Sci. Transl. Med. 10, eaau0713 (2018).
Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662–1669 (2009).
Eberling, J. L. et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980–1983 (2008).
Muramatsu, S. et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease. Mol. Ther. 18, 1731–1735 (2010).
Christine, C. W. et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson’s disease. Ann. Neurol. 85, 704–714 (2019).
Nutt, J. G. et al. Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson’s disease. Mov. Disord. 35, 851–858 (2020).
Christine, C. W. et al. Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial. Neurology 98, e40–e50 (2022).
Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383, 1138–1146 (2014).
Palfi, S. et al. Long-term follow-up of a phase i/ii study of prosavin, a lentiviral vector gene therapy for Parkinson’s disease. Hum. Gene Ther. Clin. Dev. 29, 148–155 (2018).
Milone, M. C. & O’Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529–1541 (2018).
Duncan, C. N. et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 391, 1287–1301 (2024).
Williams, D. A. Myelodysplasia after lentiviral gene therapy. Reply. N. Engl. J. Med. 391, 2384 (2024).
Hudry, E. & Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839–862 (2019).
Mendell, J. R. et al. Current clinical applications of in vivo gene therapy with AAVs. Mol. Ther. 29, 464–488 (2021).
Tang, S. et al. Hippocampus-targeted BDNF gene therapy to rescue cognitive impairments of Alzheimer’s disease in multiple mouse models. Genes Dis. 13, 101649 (2025).
High, K. A. Gene transfer as an approach to treating hemophilia. Circ. Res. 88, 137–144 (2001).
Bristol, J. A., Shirley, P., Idamakanti, N., Kaleko, M. & Connelly, S. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol. Ther. 2, 223–232 (2000).
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).
Li, H. et al. A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections. J. Neurosci. Methods 251, 99–107 (2015).
Lei, X. et al. 1-Methyl-4-phenylpyridinium stereotactic infusion completely and specifically ablated the nigrostriatal dopaminergic pathway in rhesus macaque. PLoS ONE 10, e0127953 (2015).
Smith, R. D., Zhang, Z., Kurlan, R., McDermott, M. & Gash, D. M. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52, 7–16 (1993).
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
Thomas, B. A. et al. PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Phys. Med. Biol. 61, 7975–7993 (2016).
Zhang, T., Nie, B., Liu, H. & Shan, B. Unified spatial normalization method of brain PET images using adaptive probabilistic brain atlas. Eur. J. Nucl. Med. Mol. Imaging 49, 3073–3085 (2022).
